Clobazam (Onfi)
Small molecule
Evidence outlook
Approved: Epilepsy (label: adjunctive treatment of seizures associated with Lennox-Gastaut syndrome, age 2 and older), Lennox-Gastaut Syndrome, Developmental and Epileptic Encephalopathies
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00518713 NCT00518713 · Epilepsy, Epilepsy, Generalized, Seizures The study randomly assigned 238 participants to low-, medium-, or high-dose clobazam or placebo, with participants, care providers, and investigators masked to treatment. Its clinical primary endpoint—percent reduction in drop seizures—was statistically better than placebo for all three doses, supporting a strong evidence grade. Registry: NCT00518713 | 3 | Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period) 2009-12 | Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100) | Reliable signal | link ↗ |
View 1 more trial
NCT01160770 NCT01160770 · Lennox-Gastaut Syndrome The study was an explicitly described open-label rollover from the prior double-blind studies 13108A/OV1002/NCT00162981 and 13110A/OV1012/NCT00518713, with 267 participants and no randomization, masking, or control arm in this extension. Its primary clinical endpoint was reported descriptively rather than as a controlled comparison, so the findings provide limited evidence about clobazam's treatment effect despite the large enrollment and long follow-up. Registry: NCT01160770 | 3 | Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment (Baseline to month 36); Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the Last 30-day Assessment (Baseline to month 36) 2012-02 | Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment (Baseline to month 36): Clobazam 92.3 percentage of drop seizures (range -588 to 100) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 4 (3)
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 4 (1)
What this study did
Competitive landscape
Other GABA-A receptor drugs
Diazepam (Diastat), Diazepam (Valium), Diazepam (Valtoco), Ganaxolone, Lorazepam and 9 more. Compare all 15 GABA-A receptor drugs
This mechanism is crowded: 14 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Developmental and Epileptic Encephalopathies: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Clobazam (Onfi): this drug | Approved | Small molecule | GABA-A receptor | Reliable signal | NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100) | |
| Cannabidiol (Epidiolex) | Approved | Small molecule | GPR55 / TRPV1 / adenosine transport (multi-target), cannabinoid | Reliable signal | NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2) | |
| Clobazam (Sympazan) | Approved | Small molecule | GABA-A receptor (benzodiazepine site) | not yet graded | No reviewed efficacy summary in this indication | |
| Fenfluramine (Fintepla) | Approved | Small molecule | Serotonin 5-HT2 receptors | Reliable signal | NCT03355209: Percentage change from baseline in drop-seizure frequency, fenfluramine 0.7 mg/kg/day (n=87) vs placebo (n=87): median reduction 26.5 vs 7.6 percentage points; estimated median difference -19.9 percentage points (95% CI -31.0 to -8.7; P=.001). NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966) | |
| Ganaxolone | Approved | Small molecule | GABA-A receptor | Partial signal | NCT03572933: Median percentage change in 28-day major motor seizure frequency: ganaxolone -30.7% vs placebo -6.9% (p=0.0036); Hodges-Lehmann median difference -27.1% (95% CI -47.9 to -9.6), n=100 (Knight et al., Lancet Neurol 2022). | |
| Rufinamide | Approved | Small molecule | Voltage-gated sodium channel | not yet graded | No reviewed efficacy summary in this indication | |
| Stiripentol | Approved | Small molecule | GABA-A receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Vigabatrin (Sabril) | Approved | Small molecule | GABA transaminase (GABA-T) | not yet graded | No reviewed efficacy summary in this indication | |
| Vigabatrin (Vigafyde) | Approved | Small molecule | GABA transaminase (GABA-T) | not yet graded | No reviewed efficacy summary in this indication | |
| KH607 | Phase 3(overall) | Small molecule | GABA-A receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Relutrigine | Phase 3 | Small molecule | Voltage-gated sodium channel (persistent current) | not yet graded | No reviewed efficacy summary in this indication | |
| BMB-101 | Phase 2 | Small molecule | Serotonin 5-HT2C receptor (biased agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| GlyphAllo (allopregnanolone Prodrug) (SPT-300) | Phase 2(overall) | Small molecule | GABA-A receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| HS-10353 | Phase 2(overall) | Small molecule | GABA-A receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Remimazolam | Phase 1(overall) | Small molecule | GABA-A receptor | not yet graded(overall) | No reviewed efficacy summary in this indication |
Compare side by side
4 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.